Processa Pharmaceuticals (Heatwurx Acquired Promet)
7380 Coca Cola Drive
About Processa Pharmaceuticals (Heatwurx Acquired Promet)
Processa Pharmaceuticals (OTCMKTS: PCSA) was formed in October 2017 as a result of an asset acquisition of Promet Therapeutics, LLC by Heatwurx, Inc (OTCMKTS: HUWX). Processa's mission is to develop products that can improve the survival and/or quality of life for patients who have a high unmet medical need. The company is headquartered in Hanover, Maryland.
CEO: David Young
CDO: Sian Bigora
CSO: Helen Pentikis
CBO: Patrick Lin
CAO: Wendy Guy
10 articles with Processa Pharmaceuticals (Heatwurx Acquired Promet)
Processa Pharmaceuticals to Participate in Upcoming Investor ConferencesProcessa’s pipeline includes several clinical-stage drug candidates
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today that management will participate in two upcoming investor conferences: Craig-Hallum Alpha Select Virtual Conference Tuesday, Nov. 17, 2020 (one-on-one meetings only) Benchmark
Processa Pharmaceuticals Announces Third Quarter 2020 Results, Provides Corporate UpdateHighlights include closing $19.2 million public offering
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) (“Processa” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of drug products that are intended to provide treatment for and improve the survival and/or quality of life for patients who have unmet medical needs or conditions or who have no alternative treatment, today reports financial results for the third quarter of 2020.
Processa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on Nov. 12 at 5:30 p.m. ET
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients who have high unmet medical need conditions, today announces it will host a conference call and live webcast on Nov. 12, 2020, at 5:30 p.m. Eastern time to discuss its third quarter 2020 results and provide an update on the Company’s
10/16/2020Biopharma and life sciences companies bolster their leadership teams with these Movers & Shakers.
9/3/2019Rounding out the traditional summer months, last week had plenty of clinical trial news. Here’s a look at some of the top stories.
Mr. Stanker brings more than 25 years of financial and executive leadership experience to Processa in the areas of accounting principles and audit standards, regulatory reporting, and fiscal management and strategy.
Processa Pharmaceuticals Receives Orphan Designation Status For PCS499 In Necrobiosis Lipoidica From The Food And Drug Administration (FDA)
Approximately 74,000 - 185,000 people in the United States and 200,000 - 500,000 people worldwide are affected by NL.
Processa Pharmaceuticals, Inc. (OTC: PCSA) is pleased to announce it has raised a total of $6.88 million from private placements.
Processa Pharmaceuticals Announces That It Has Been Assigned The License For The Clinical Stage Compound CTP-499 And Plans To Develop The Drug In Multiple Unmet Medical Need Conditions
Processa Pharmaceuticals, Inc. (OTC: PCSA) announced today that, as agreed in the asset purchase of Promet Therapeutics, LLC, Processa has been assigned the license for CTP-499 upon Promet's exercising of the exclusive option to license in CTP-499 from Concert Pharmaceuticals, Inc.
Processa formed from the merger of Promet Therapeutics and Heatwurx, is an emerging clinical stage biotech company focused on the development of drugs for the treatment of high unmet medical need conditions.